Last mentioned: Mar 6, 2026
PROF Break-even
Target window for Profound Medical to reach cash-flow neutrality.
Kura NDA Submission
Anticipated filing for ziftomenib with the FDA.
Q4 Earnings Release
Both companies report pivotal year-end results.
CPT Code Activation
Category 1 CPT codes for TULSA-PRO go live in the U.S.
Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a pivotal shift toward commercial execution. Kura is nearing an NDA submission for its lead leukemia candidate, while Profound saw record revenue growth following the first full year of Category 1 CPT code implementation.
Kura Oncology and Profound Medical reported fourth-quarter 2025 results, highlighting a pivotal shift toward commercial execution in precision oncology and medical technology. While both companies faced revenue headwinds, Kura's launch of KOMZIFTI and Profound's surprise earnings beat signal a maturing landscape for specialized therapies.
Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a critical transition period as they navigate commercial launches and reimbursement hurdles. While both firms faced revenue headwinds, Kura's $7 billion AML opportunity and Profound's significant EPS beat underscore a shifting landscape in oncology and incision-less surgery.